Local Coverage Determination (LCD)

Immune Globulins

L34771

Expand All | Collapse All
Proposed LCD
Proposed LCDs are works in progress that are available on the Medicare Coverage Database site for public review. Proposed LCDs are not necessarily a reflection of the current policies or practices of the contractor.

Document Note

Note History

Contractor Information

LCD Information

Document Information

Source LCD ID
N/A
LCD ID
L34771
Original ICD-9 LCD ID
Not Applicable
LCD Title
Immune Globulins
Proposed LCD in Comment Period
N/A
Source Proposed LCD
N/A
Original Effective Date
For services performed on or after 10/01/2015
Revision Effective Date
For services performed on or after 02/29/2024
Revision Ending Date
N/A
Retirement Date
N/A
Notice Period Start Date
N/A
Notice Period End Date
N/A

CPT codes, descriptions, and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Issue

Issue Description

Biannual review completed with no change in coverage.

Issue - Explanation of Change Between Proposed LCD and Final LCD

CMS National Coverage Policy

CMS Pub 100-02 Medicare Benefit Policy Manual, Chapter 15 – Covered Medical and Other Health Services, Section 50.6 – Coverage of Intravenous Immune Globulin for Treatment of Primary Immune Deficiency Diseases in the Home.

CMS Pub 100-03 Medicare National Coverage Determination (NCD) Manual, Chapter 1, Part 4, Section 250.3 – Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases.

CMS Pub 100-04 Medicare Claims Processing Manual, Chapter 17 – Drugs and Biologicals, Section 80.6 – Intravenous Immune Globulin (Change Requests 2149, 3745, 4244, 5635, 5643, and 5981).

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Immune serums (immune globulin) provide passive immunity to infectious disease. The protection will be of rapid onset, but of short duration (1-3 months). Immune sera are obtained from pooled human plasma of either general population donors or hyperimmunized donors. It may be administered either by intravenous (IV) or intramuscular (IM) injection.

  1. Immune globulin is available in broad-spectrum form, or disease-specific hyperimmune serum.
    1. Gamma Globulin; intramuscular IG, Gamma Globulin, ISG, Gamastan, Gammar, is indicated for the following conditions:
      1. Hepatitis A exposure.
      2. Measles (Rubeola): for a susceptible patient (has not been vaccinated or had measles and is at high risk for complication) who has been exposed less than 3 days prior to treatment.
      3. Rubella: for a woman in early pregnancy, who is exposed to the virus and does not have immunity.
      4. Varicella: for passive immunization in immunosuppressed patients when varicella zoster immunoglobulin is not available.
      5. Immunoglobulin deficiency: for prevention of serious infection when circulating IgG levels are low. Prophylactic therapy, especially against infections due to encapsulated bacteria, is often effective in Bruton-type, sex-linked congenital agammaglobulinemia, agammaglobulinemia associated with thymoma, and acquired agammaglobulinemia.
    2. Specific hyperimmune serum globulin includes several different disease-specific drugs.
      1. Hepatitis B serum is indicated post-exposure for transient prevention of hepatitis B infection.
      2. Rabies serum is indicated post-exposure for transient prevention of rabies infection when the patient has not been completely immunized with the vaccination.
      3. Vaccinia serum is indicated for transient prevention of, or modification of aberrant infections induced by vaccinia (smallpox) vaccine, the vaccinia virus, such as eczema vaccinatum, some cases of progressive vaccinia, and possibly ocular vaccinia.
      4. Varicella-zoster serum is indicated for transient prevention of varicella-zoster infection in exposed, susceptible individuals who have a greater risk of complications from varicella. Documentation in the progress notes must indicate one of the following complicating conditions to verify medical necessity:
        - Personal history of leukemia or lymphoma
        - HIV infection
        - Current immunosuppressive therapy
        - A newborn with exposure to chickenpox (the documentation must indicate why the newborn is at increased risk; e.g., if the mother was exposed within 5 days of delivery).
      5. Tetanus serum is indicated for transient protection against tetanus post-exposure to tetanus. Documentation in the progress notes must identify the following:
        - The wound is other than a clean minor wound, and the date of the injury;
        - The active immunization with tetanus toxoid is unknown or uncertain; or
        - The patient has received either less than 2 prior doses of tetanus toxoid; or 2 prior doses of tetanus toxoid, but there has been a delay of 24 hours or more between the time of injury and the initiation of tetanus prophylaxis.
      6. Cytomegalovirus (CMV) immune globulin intravenous (CMV-IGIV) (human) per vial is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, heart, stem cell, and pancreas. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir.
      7. Hepatitis B immune globulin (HepaGam B) intramuscular, 0.5 ml is indicated for the treatment of acute exposure to blood containing Hepatitis B Surface Antigen (HBsAg), perinatal exposure of infants born to HBsAg positive mothers, sexual exposure to HBsAg-positive persons, and household exposure to persons with acute HBV infection.
      8. HepaGam B intravenously is indicated for the prevention of Hepatitis B recurrence following a liver transplantation, in HBsAg-positive liver transplant patients.
      9. Crotalidae polyvalent immune FAB (OVINE), (CroFab)
        CroFab is indicated for the management of patients with minimal or moderate envenomation from North American rattlesnakes, copperheads, and cottonmouths/water moccasins. Early use of CroFab (within 6 hours of snakebite) is advised to prevent clinical deterioration and the occurrence of systemic coagulation abnormalities.
  2. Intravenous immune globulin (Sandoglobulin, Venoglobulin-I, Privigen, Gamunex, Octagam, Gammagard liquid, Flebogamma/Flebogamma DIF, Carimune, Gammaplex, Bivigam) provides immediate antibody levels. IVIG may be indicated for the following conditions:
    1. Immunodeficiency Syndrome: to include congenital agammaglobulinemia such as x-linked agammaglobulinemia, common variable hypoglobulinemia, x-linked immunodeficiency with hyper IGM, combined immunodeficiency.
    2. Primary thrombocytopenia.
    3. Alloimmune thrombocytopenia, refractoriness to platelet transfusions. Routine use is not indicated. IVIG may have a role in patients with severe thrombocytopenia of documented immune basis for whom other modalities are unsuccessful or contraindicated.
    4. Post-transfusion purpura. IVIG may be considered as first-line therapy in severely affected patients.
    5. Lymphoid Leukemia with either hypogammaglobulinemia or recurrent bacterial infections.
    6. Autoimmune hemolytic anemia (AIHA). Routine use is not indicated. IVIG may have a role in patients with warm-type AIHA that does not respond to corticosteroids.
    7. Immune-mediated neutropenia. Routine use is not indicated. IVIG may have a role in severe illness that does not respond to other modalities or when the latter are contraindicated.
    8. Multiple Myeloma. Routine use is not indicated. It may have a role in patients with stable (plateau phase) disease and high risk of recurrent infections.
    9. Pediatric intractable epilepsy. Routine use is not indicated. IVIG may have a role in certain syndromes as a last resort, especially in patients who may be candidates for surgical resection.
    10. Guillain-Barré syndrome. IVIG is recommended as an equivalent alternative to plasma exchange in children and adults.
    11. Myasthenia gravis (MG). Routine use is not indicated. IVIG may be considered in patients with severe MG to treat acute severe decompensation when other treatments have been unsuccessful or are contraindicated.
    12. Eaton-Lambert Syndrome. This is an immune-mediated, myasthenia-like syndrome. Treatment with IVIG is directed at decreasing the autoimmune response.
    13. Polyneuropathy, chronic inflammatory demyelinating. IVIG is recommended as an equivalent alternative to plasma exchange in adults.
    14. Multifocal motor neuropathy. The routine use of IVIG is not usually recommended. IVIG may be considered in patients who have progressive, symptomatic multifocal motor neuropathy that has been diagnosed on the basis of electrophysiologic findings that rule out other possible conditions that may not respond to this treatment.
    15. Dermatomyositis. Routine use is not indicated. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.
    16. Polymyositis. Routine use is not indicated. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.
    17. Systemic lupus erythematosus (SLE). Routine use is not indicated. IVIG may be used for patients with severe active SLE for whom other interventions have been unsuccessful or intolerable.
    18. Systemic sclerosis dermatomyositis overlap syndrome. Routine use is not indicated. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.
    19. Kawasaki disease.
    20. Severe Vasculitic Syndromes, systemic (polyarteritis nodosa), Churg-Strauss Vasculitis, and livedoid vasculitis (atrophie blanche). Evidence does not support routine use of IVIG. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.
    21. Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome. Evidence does not support routine use of IVIG. It will be covered if it is refractory to conventional therapy.
    22. Pemphigoid gestationis that is refractory to conventional therapy.
    23. Pyoderma gangrenosum that is refractory to conventional therapy.
    24. Neonatal alloimmune thrombocytopenia. Routine use of IVIG is not recommended. It is recommended in severely thrombocytopenic, symptomatic neonates who are at high risk of developing intracranial hemorrhage when other interventions have been unsuccessful, become intolerable, or are contra-indicated.
    25. IVIG may be indicated for high-risk pregnant women who have had a history of a previously affected infant with fetal-neonatal thrombocytopenia.
    26. Wiskott-Aldrich Syndrome.
    27. Anemia due to pure red cell aplasia.
    28. Human Immunodeficiency Virus (HIV) infection. IVIG will be covered for patients infected with HIV to reduce significant bacterial infection when all the following coverage indicators are present: a) age less than 13 years old; b) evidence of either qualitative or quantitative humoral immunologic defects and c) current bacterial infections, despite appropriate antimicrobial prophylaxis. Dosage Guidelines: 400 mg/kg body weight given every 28 days.
    29. Autoimmune mucocutaneous blistering disease is covered by a National Coverage Determination (See Pub 100-3: Medicare National Coverage Determination Manual Chapter 1, Part 4 Section 250.3).
    30. Stiff-man syndrome. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.
    31. Desensitization for a pre-kidney transplantation in patients with a panel reactive antibody (PRA) of 80% or below. Use in patients with a PRA of 81-100% is considered to be experimental/ investigation and is therefore not covered. Post transplantation to prevent rejection remains covered without regard to antibody levels.
    32. Scleromyxedema, mucinosis of the skin, focal mucinosis, lichen myxedematosus, or reticular erythematous mucinosis.
  3. Subcutaneous immune globulin (Hyqvia)
    1. Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of Primary Immunodeficiency (PI) in adults. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Hyqvia is administered subQ on an infusion pump which has the ability to titrate the flow rate up or down if required to improve tolerability. WPS GHA Part B will cover the cost as “incident to” for a maximum of 2 episodes to provide teaching in the office setting, effective 12/15/2016. For subsequent doses and titration, coverage shifts to the DME MAC.
Summary of Evidence

N/A

Analysis of Evidence (Rationale for Determination)

N/A

Proposed Process Information

Synopsis of Changes
Changes Fields Changed
N/A
Associated Information
Sources of Information
Bibliography
Open Meetings
Meeting Date Meeting States Meeting Information
N/A
Contractor Advisory Committee (CAC) Meetings
Meeting Date Meeting States Meeting Information
N/A
MAC Meeting Information URLs
N/A
Proposed LCD Posting Date
Comment Period Start Date
Comment Period End Date
Reason for Proposed LCD
Requestor Information
This request was MAC initiated.
Requestor Name Requestor Letter
View Letter
N/A
Contact for Comments on Proposed LCD

Coding Information

Bill Type Codes

Code Description

Please accept the License to see the codes.

N/A

Revenue Codes

Code Description

Please accept the License to see the codes.

N/A

CPT/HCPCS Codes

Please accept the License to see the codes.

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph:

N/A

Group 1 Codes:

N/A

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph:

N/A

Group 1 Codes:

N/A

N/A

Additional ICD-10 Information

General Information

Associated Information

Documentation Requirements
Medical records must include the indications to support using IVIG. For those indications stating routine use is not indicated, the medical record must document the interventions that were unsuccessful or the reason they were not tolerated.

Documentation must support objective response for continued coverage. Medical Records must be made available to the Contractor upon request.

Utilization Guidelines

Sources of Information
N/A
Bibliography

Branch DW, Porter TF, Paidas MJ, Belfort MA, Gonik B. Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. Journal of Allergy and Clinical Immunology. 2001;108:133-138.

Bussel JB. Alloimmune thrombocytopenis in the fetus and newborn. Seminars in Thrombosis and Hemostasis. 2001;(3):245-252.

Callen JP, Jorizzo JL. Skin signs of systemic disease. Best Practice of Medicine. 2000;

CytoGam™ Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV) package insert.

Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumor necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. British Journal of Dermatology. 2002;146(4):707-708.

Gebel HM, Halloran PF. Making sense of desensitization. American Journal of Transplantation. 2010;10:1-2.

Jordan SC, Toyoda M, Jahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. American Journal of Transplantation. 2011;1:196-202.

Kreuter A, et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. Journal of American Academic Dermatology. 2004;51(4).

Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. American Journal of Transplantation. 2010;10:1-9.

Rongioletti F. Scleromyxedema. UpToDate. Alphen aan den Rijn, The Netherlands: Wolters Kluwer. 2015.

Rutter A, Luger T. High-dose intravenous immunoglubulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. Journal of the American Academy of Dermatology. 2001;1010-1024.

Silver RM, Porter TF, Branch Esplin MS, Scott JR. Neonatal alloimmune thrombocytopenia: antenatal management. American Journal of Obstetrics and Gynecology. 2000;182(5):1233-1238.

Revision History Information

Revision History Date Revision History Number Revision History Explanation Reasons for Change
02/29/2024 R22

Posted 02/29/2024: Biannual review completed with no change in coverage.

  • Other ((Review))
12/01/2022 R21

Posted 12/01/2022: Review completed 11/02/2022 with no change in coverage. Updated formatting under CMS National Coverage Policy. Relocated references listed under Sources of Information to Bibliography and corrected to reflect AMA formatting. Minor grammatical errors also corrected throughout the LCD.

  • Other (Review)
10/01/2020 R20

10/29/2020 Under CMS National Coverage Policy, removed language no longer relevant.
Under Coverage Indications, Limitations, and/or Medical Necessity Section A. 2. i., added additional FDA indications that were unintentionally left out. Review completed 09/23/2020.

  • Provider Education/Guidance
  • Other (Review)
11/01/2019 R19

Change Request 10901 Local Coverage Determinations (LCDs): it will no longer be appropriate to include Current Procedure Terminology (CPT)/Health Care Procedure Coding System (HCPCS) codes or International Classification of Diseases Tenth Revision-Clinical Modification (ICD-10-CM) codes in the LCDs. All CPT/HCPCS, ICD-10 codes, and Billing and Coding Guidelines have been removed from this LCD and placed in the Billing and Coding Article related to this LCD. Consistent with Change Request 10901, if any language from IOMs and/or regulations was present in the LCD, it has been removed and the applicable manual/regulation has been referenced.

  • Revisions Due To Code Removal
08/13/2019 R18

08/01/2019 Added ICD-10 codes that support medical necessity to Group 12 table to include D80.6, D80.7, D81.5, D82.1, D82.4 and G11.3 based on CR 11295: Update to Coverage of Intravenous Immune Globulin for Treatment of Primary Immune Deficiency Diseases in the Home. Effective 08/13/2019. 

  • Revisions Due To ICD-10-CM Code Changes
01/01/2019 R17

01/01/2019 Annual review done 11/30/2018.

  • Other (Annual Review)
01/01/2018 R16

01/01/2018 Annual review done 12/01/2017, no change in coverage.

  • Other (Annual Review)
10/01/2017 R15

10/01/2017 ICD-10 code updates: to Group 7: deleted code T07 and added codes T07.XXXA, T07.XXXD, and T07.XXXS; to Group 12 had a description change to codes M33.00, M33.01, M33.02, M33.09, M33.10, M33.11, M33.12, and M33.19 and added codes M33.03, M33.13 and M33.93. Formatting changes made. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

  • Revisions Due To ICD-10-CM Code Changes
07/01/2017 R14

07/01/2017 In Group 12: removed asterisk for code G61.89, removed asterisk clarification after Group 12 for code G61.89, and added code G61.82 (Multifocal motor neuropathy).


 

  • Revisions Due To ICD-10-CM Code Changes
01/01/2017 R13 01/01/2017 Annual review done 12/02/2016. No change in coverage.
  • Other (Annual review)
12/15/2016 R12 12/01/2016 Added “incident to” coverage language criteria for subcutaneous immune globulin J1575 (Hyqvia). Added Group 13 Paragraph and Group 13 table for code J1575 and diagnosis codes D80.0, D81.0, D81.1, D81.2, D81.6, D81.7, D81.89, D82.0, D83.0, D83.1, D83.2, D83.8, and D83.9, effective 12/15/2016.
  • Other
10/01/2016 R11 10/01/2016 Per ICD-10 annual code update: In group 10: deleted code Z22.51, effective 10/01/2016.
  • Revisions Due To ICD-10-CM Code Changes
05/01/2016 R10 05/01/2016 Added diagnosis code Z94.2 to Group 8 list of covered codes, effective 10/01/2015.
  • Other (Corrected Revision Effective Date from 04/01/2016 to 05/01/2016)
04/01/2016 R9 05/01/2016 Added diagnosis code Z94.2 to Group 8 list of covered codes, effective 10/01/2015.
  • Other (Code Update)
  • Revisions Due To ICD-10-CM Code Changes
04/01/2016 R8 04/01/2016 Added diagnosis code L98.5 to Group 12 list of covered codes, effective 04/01/2016. Updated Sources of Information. Formatting changes made.
  • Other (Code Update)
  • Revisions Due To ICD-10-CM Code Changes
01/01/2016 R7 03/01/2016 Added diagnosis code D81.9 to Groups 1 and 12 list of covered codes, effective 10/01/2015.Removed Group 13 Paragraph and Group 13 table for code J1575 and diagnosis codes D80.0, D81.0, D81.1, D81.2, D81.6, D81.7, D81.89, D82.0, D83.0, D83.1, D83.2, D83.8, and D83.9, effective 01/01/2016; published in error.
  • Revisions Due To CPT/HCPCS Code Changes
  • Other (Code Update)
  • Revisions Due To ICD-10-CM Code Changes
01/01/2016 R6 02/01/2016 Correction to Revision History Explanation from 01/01/2016: Diagnosis code D81.1 was listed twice; one of them should be D81.0.
  • Typographical Error
01/01/2016 R5 01/01/2016 Annual review done 12/08/2015. Formatting changes made. Per Annual CPT/HCPCS Code Update added code J1575 and diagnosis codes D80.0, D81.1, D81.1, D81.2, D81.6, D81.7, D81.89, D82.0, D83.0, D83.1, D83.2, D83.8, and D83.9 (Group 13 Paragraph).
  • Revisions Due To CPT/HCPCS Code Changes
  • Other (Annual review and 2016 CPT/HCPCS Code Changes)
10/01/2015 R4 12/01/2015 Added diagnosis code D83.9 to Group 12 list of covered codes, effective 10/01/2015. Removed CAC information.
  • Other (Other Revision Due TO ICD-10-CM Code Changes)
  • Revisions Due To ICD-10-CM Code Changes
10/01/2015 R3 10/06/2015 - Due to CMS guidance, we have removed the Jurisdiction 8 Notice and corresponding table from the CMS National Coverage Policy section. No other changes to policy or coverage.
  • Other
10/01/2015 R2 09/01/2015 Added diagnosis code D83.1 (Common variable immunodeficiency with predominant immunoregulatory T-cell disorders) to group 1 list of covered codes and Group 12 list of covered codes.
  • Other
  • Revisions Due To ICD-10-CM Code Changes
10/01/2015 R1 01/01/2015 Annual review done 12/04/2014. Formatting and grammar changes made. Updated sources of information. No change in coverage.
  • Other
N/A

Associated Documents

Attachments
N/A
Related Local Coverage Documents
Articles
A57554 - Billing and Coding: Immune Globulins
Related National Coverage Documents
N/A
Public Versions
Updated On Effective Dates Status
02/21/2024 02/29/2024 - N/A Currently in Effect You are here
11/22/2022 12/01/2022 - 02/28/2024 Superseded View
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A

Read the LCD Disclaimer